Trice Medical gets $11.6M; Opinion: in defense of robotic surgery;

@FierceMedDev: Stryker delivers positive Q2 numbers but stays mum on inversion. ICYMI Friday | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery article | Follow @MichaelGFierce

@VarunSaxena2: Venture capitalist spending bonanza lifts med tech investment in Q2. Report | Follow @VarunSaxena2

@EmilyWFierce: DC journo raises $75K on Kickstarter to fly drones over factory farms, circumvent "ag-gag" laws. More from NPR | Follow @EmilyWFierce

> Trice Medical announced the close of an $11.6 million Series B financing that will go to fund marketing for its diagnostic arthroscopy product, mi-eye. The lead investor was Safegaurd Sciences which holds a 9.6% position. Story

> Dr. Catherine Mohr, senior director of medical research at Intuitive Surgical ($ISRG), defends the use of robot-assisted surgery citing the importance of keeping procedures minimally invasive. Article

> Brainlab has introduced Elements Automatic Brain Metastases Planning, a new software which the company hopes will make planning for stereotactic radiosurgery easier. More

Biotech News

@FierceBiotech: Will AbbVie now emerge as the next megamerger target? More | Follow @FierceBiotech

@JohnCFierce: New Science Ventures joins the biotech VC boom, plots $100M fund. News | Follow @JohnCFierce

@DamianFierce: Cutting jobs, ditching "unpromising" R&D programs -- $AGN is slowly becoming the company $VRX wants it to be. Just, you know, minus $VRX. | Follow @DamianFierce

@EmilyMFierce: What?! Update on the Found Vials: There Weren't 6; There Were 327. (Not All of Them Were Smallpox.) More from Wired | Follow @EmilyMFierce

> Allergan aims ax at R&D, eliminating 1,500 jobs in bitter takeover fight. Report

> Cerecor raises $16M for PhII study of 'Special K' depression remedy. Article

> J&J partner Aduro grabs an FDA 'breakthrough' nod for its immuno-oncology combo. News

Pharma News

@FiercePharma: Tops this weekend: AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future. News | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: ICYMI: Teva says it is cooperating with probe by Israel into source of blood infections taking Teva product. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan plotting 1,500 job cuts as part of restructuring. Release | Follow @CarlyHFierce

> Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Article

> Animal health companies not exempt from FDA marketing regs, either. Item

> Roche CEO: No appetite for expensive megadeals here. Story

CRO News

> Amid global expansion, India's GVK focuses on clinical development. Story

> CRO Chiltern snags rival Ockham to bolster its oncology footprint. Report

> Post-buyout Harlan inks a CRO partnership with Fluofarma. Article

> Theorem eyes an Indian expansion with latest partnership. Story

> Catalent shoots for $872M in a blockbuster IPO. News

Biotech IT News

> Google-backed service provider gives clients direct control of robot-run lab. Report

> FDA adds recalls API as openFDA initiative gathers pace. News

> Bioinformatics skills help Codexis strike $25M deal with GSK. Story

> Report: Development IT hit hard in Novartis cutbacks. Article

> Novartis and Google team up to commercialize 'smart' contact lenses. Item

Animal Health News

> Seizures in horses in Kentucky focus attention on drug compounding. More

> Virbac H1 sales hurt by Iverhart recall in U.S. Report

> Sanofi's Merial revives heartworm treatment. Article

> Why is there increased activity in animal health IPOs? Item

> France's AB Science warned by FDA for its canine cancer drug promotion. Story

> Merck prods cattle producers to help it test the safety of withdrawn Zilmax. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.